Bendamustine Treatment in Refractory or Relapsed T Cell Lymphomas: A Retrospective Multicenter Study

被引：0

作者：

Reboursiere, Emilie ^{[1
]}

Le Bras, Fabien ^{[2
]}

Morschhauser, Franck ^{[3
]}

Gyan, Emmanuel ^{[4
]}

Clavert, Aline ^{[5
]}

Malak, Sandra ^{[6
]}

Sibon, David ^{[7
]}

Damge, Marion ^{[8
]}

Gardin, Claude ^{[9
]}

Fornecker, Luc-Matthieu ^{[10
]}

Garidi, Reda ^{[11
]}

Tricot, Sabine ^{[12
]}

Houot, Roch ^{[13
]}

Joly, Bertrand ^{[14
]}

Abarah, Wajed ^{[15
]}

Choufi, Bachra ^{[16
]}

Pham, Anne-dominique ^{[1
]}

Chantepie, Sylvain P. ^{[17
]}

Fruchart, Christophe ^{[1
]}

Gac, Anne-Claire ^{[1
]}

Ollivier, Catherine ^{[1
]}

Marin, Emilie ^{[1
]}

Safar, Violaine ^{[18
]}

Parcelier, Anne ^{[19
,20
]}

Maisonneuve, Herve ^{[21
]}

Bachy, Emmanuel ^{[22
]}

Cartron, Guillaume ^{[23
]}

Jaccard, Arnaud ^{[24
]}

Tournilhac, Olivier ^{[25
]}

Rossi, Cedric ^{[26
]}

Perrot, Aurore ^{[27
]}

Martignoles, Jean-Alain ^{[28
]}

Tilly, Herve ^{[29
]}

Damaj, Gandhi ^{[30
]}

机构：

[1] CHU Caen, F-14000 Caen 5, France

[2] APHM, Bobigny, France

[3] Univ Lille 2, Ctr Hosp Univ, Hematol, Lille, France

[4] CHU Tours, UMR CNRS 7292, Serv Hematol & Therapie Cellulaire, Tours, France

[5] CHU Angers, Hematol, Angers, France

[6] CHU Curie, Paris, France

[7] APHP Necker, Paris 15, France

[8] Inst J Paoli I Calmettes, F-13009 Marseille, France

[9] Hop Avicenne, Hematol, F-93009 Bobigny, France

[10] CHU Strasbourg, F-67000 Strasbourg, France

[11] Hosp St Quentin, St Quentin en Yvelines, France

[12] CHU, Valenciennes, France

[13] Stanford Univ, Stanford, CA 94305 USA

[14] Ctr Hosp Sud Francilien, Dept Hematol, Corbeil Essonnes, France

[15] Hosp Meaux, Meaux, France

[16] Hop Boulogne Sur Mer, Boulogne, France

[17] Caen Univ Hosp, Dept Haematol, Caen, France

[18] Hosp Civils Lyon, Dept Hematol, Pierre Benite, France

[19] Ctr Hosp Univ, Hematol, Amiens, France

[20] Chu Amiens, Salouel, France

[21] CH, Dept Hematol & Oncol, La Roche Sur Yon, France

[22] Hosp Lyon, Lyon, France

[23] CHR Univ Tours, Montpellier, France

[24] CHU Limoges, Dept Hematol, Ctr Natl Reference Malad Rares Amylose AL & Autre, Limoges, France

[25] CHU Clermont Ferrand, Clermont Ferrand 1, France

[26] CHU, Dijon, France

[27] CHU, Vandoeuvre Les Nancy, France

[28] St Etienne Univ Hosp, St Etienne, France

[29] Ctr Henri Becquerel, Serv Hematol Clin, F-76038 Rouen, France

[30] CHU Caen, Dept Hematol, F-14000 Caen, France

来源：

BLOOD | 2015年 / 126卷 / 23期

关键词：

D O I：

暂无

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

引用

页数：3

共 50 条

[41] Recent Advances in the Management of Relapsed and Refractory Peripheral T-Cell Lymphomas
Braunstein, Zachary
Ruiz, Miguel
Hanel, Walter
Shindiapina, Polina
Reneau, John C.
Brammer, Jonathan E.
JOURNAL OF PERSONALIZED MEDICINE, 2022, 12 (06):
[42] A multicenter phase II study of bendamustine, rituximab, and cytarabine (BRAC) for relapsed or refractory patients with follicular lymphoma or mantle cell lymphoma
Nobuhiko Nakamura
Senji Kasahara
Junichi Kitagawa
Hiroshi Nakamura
Michio Sawada
Kenji Fukuno
Yuhei Shibata
Yuto Kaneda
Takeshi Hara
Nobuhiro Kanemura
Hisashi Tsurumi
Masahito Shimizu
Experimental Hematology & Oncology, 11
[43] A MULTICENTER PHASE II STUDY OF BENDAMUSTINE WITH RITUXIMAB IN PATIENTS WITH RELAPSED/REFRACTORY DIFFUSE LARGE B-CELL LYMPHOMA (DLBCL)
Kim, W. S.
Ando, K.
Niitsu, N.
Ogura, M.
Takahashi, N.
Uike, N.
Eom, H. Seok
Chae, Y. S.
Tobinai, K.
Terauchi, T.
Tateishi, U.
Tatsumi, M.
Suh, C.
ANNALS OF ONCOLOGY, 2012, 23 : 94 - 94
[44] Bendamustine mitoxantrone and rituximab (BMR):: A new effective regimen for refractory or relapsed indolent lymphomas
Weide, R
Heymanns, J
Gores, A
Köppler, H
LEUKEMIA & LYMPHOMA, 2002, 43 (02) : 327 - 331
[45] A multicenter phase II study of bendamustine, rituximab, and cytarabine (BRAC) for relapsed or refractory patients with follicular lymphoma or mantle cell lymphoma
Nakamura, Nobuhiko
Kasahara, Senji
Kitagawa, Junichi
Nakamura, Hiroshi
Sawada, Michio
Fukuno, Kenji
Shibata, Yuhei
Kaneda, Yuto
Hara, Takeshi
Kanemura, Nobuhiro
Tsurumi, Hisashi
Shimizu, Masahito
EXPERIMENTAL HEMATOLOGY & ONCOLOGY, 2022, 11 (01)
[46] Multicenter Phase II Study of Bendamustine Plus Rituximab in Patients With Relapsed or Refractory Diffuse Large B-Cell Lymphoma
Ohmachi, Ken
Niitsu, Nozomi
Uchida, Toshiki
Kim, Seok Jin
Ando, Kiyoshi
Takahashi, Naoki
Takahashi, Naoto
Uike, Naokuni
Eom, Hyeon Seok
Chae, Yee Soo
Terauchi, Takashi
Tateishi, Ukihide
Tatsumi, Mitsuaki
Kim, Won Seog
Tobinai, Kensei
Suh, Cheolwon
Ogura, Michinori
JOURNAL OF CLINICAL ONCOLOGY, 2013, 31 (17) : 2103 - +
[47] CYCLOSPORINE TREATMENT OF REFRACTORY T-CELL LYMPHOMAS
COOPER, DL
BRAVERMAN, IM
SARRIS, AH
DURIVAGE, HJ
SAIDMAN, BH
DAVIS, CA
HAIT, WN
CANCER, 1993, 71 (07) : 2335 - 2341
[48] Brentuximab Vedotin in the Treatment of Cutaneuous T Cell Lymphomas: A Multicenter, Retrospective, Case-Control Study from Italy
Morsia, Erika
Grandi, Vieri
Zizzari, Annagiulia
Loseto, Giacomo
Fava, Paolo
Violetti, Silvia Alberti
Pileri, Alessandro
Broccoli, Alessandro
Vitiello, Paola
Sica, Antonello
Nassi, Luca
Di Riamondo, Cosimo
Quaglino, Pietro
Pimpinelli, Nicola
Berti, Emilio
Zinzani, Pier Luigi
Rupoli, Serena
BLOOD, 2023, 142
[49] Multicenter phase II study of bendamustine for relapsed or refractory indolent B-cell non-Hodgkin lymphoma and mantle cell lymphoma
Ohmachi, Ken
Ando, Kiyoshi
Ogura, Michinori
Uchida, Toshiki
Itoh, Kuniaki
Kubota, Nobuko
Ishizawa, Kenichi
Yamamoto, Joji
Watanabe, Takashi
Uike, Naokuni
Choi, Ilseung
Terui, Yasuhito
Usuki, Kensuke
Nagai, Hirokazu
Uoshima, Nobuhiko
Tobinai, Kensei
CANCER SCIENCE, 2010, 101 (09) : 2059 - 2064
[50] Bendamustine and rituximab (BR) are effective in the treatment of relapsed or refractory indolent and mantle-cell lymphomas: Long-term follow-up of a phase II study
Rummel, M. J.
Atta, J.
Welslau, M.
Kofahl-Krause, D.
von Gruenhagen, U.
Schalk, K.
Boeck, H. P.
Banat, A. G.
Knauf, W.
Niederle, N.
JOURNAL OF CLINICAL ONCOLOGY, 2007, 25 (18)

← 1 2 3 4 5 →